Overactive Bladder Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Flat Magnetic Stimulation for Urge Urinary Incontinence
Conclusions: The new FMS represents a promising non-pharmacological option for the treatment of naive and refractory OAB.PMID:38004048 | PMC:PMC10673601 | DOI:10.3390/medicina59111999 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - November 25, 2023 Category: Universities & Medical Training Authors: Marta Barba Alice Cola Giorgia Rezzan Clarissa Costa Ilaria Re Silvia Volont è Stefano Terzoni Matteo Frigerio Serena Maruccia Source Type: research

Age-dependent effects of the β < sub > 3 < /sub > adrenoceptor agonist CL316,243 on human and rat detrusor muscle strips
In conclusion, our findings suggest differential age-dependent changes in human β3 adrenoceptor-dependent attenuation of detrusor contraction in terms of electromechanical versus pharmacomechanical coupling; they may help understand the differential responsiveness of OAB patients to β3 agents.PMID:37993748 | DOI:10.1007/s00424-023-02877-x (Source: Pflugers Archiv : European Journal of Physiology)
Source: Pflugers Archiv : European Journal of Physiology - November 22, 2023 Category: Physiology Authors: Charlotte Petereit Katrin Porath Simone Rackow Karoline Kernig Oliver W Hakenberg R üdiger Köhling Timo Kirschstein Source Type: research

Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial
ConclusionPatients ’ perception of pain, efficacy, and adverse events did not significantly differ between patients receiving 10 and those receiving 20 injections of 100 units of onabotulinumtoxinA. (Source: International Urogynecology Journal and Pelvic Floor Dysfunction)
Source: International Urogynecology Journal and Pelvic Floor Dysfunction - November 22, 2023 Category: OBGYN Source Type: research

Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial
ConclusionPatients ’ perception of pain, efficacy, and adverse events did not significantly differ between patients receiving 10 and those receiving 20 injections of 100 units of onabotulinumtoxinA. (Source: International Urogynecology Journal)
Source: International Urogynecology Journal - November 22, 2023 Category: OBGYN Source Type: research